261 related articles for article (PubMed ID: 31563512)
1. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
[TBL] [Abstract][Full Text] [Related]
2. An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals.
Campbell JM; Colombo S; Doyle JL; Filoti DI; Hübner G; Magnenat L; Nowinski AK; Pavon JA; Singh SM; Vo LR; Woods JM; Stokes ESE
J Pharm Sci; 2024 Mar; 113(3):505-512. PubMed ID: 38103689
[TBL] [Abstract][Full Text] [Related]
3. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
[TBL] [Abstract][Full Text] [Related]
4. An Intercompany Perspective on Compatibility and In-use Stability Studies to Enable Administration Of Biopharmaceutical Drug Products.
Kamen DE; Crotts G; Narasimhan C; Hu Q; Bhargava AC; Muthurania K; Burton L; Gbormittah FO; Mathews L; Mills B; Hodge T; Saluja S; Singh SN; Tabish T; Wu Y; Stokes ESE
J Pharm Sci; 2022 Apr; 111(4):1092-1103. PubMed ID: 34600941
[TBL] [Abstract][Full Text] [Related]
5. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.
Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P
Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104
[TBL] [Abstract][Full Text] [Related]
6. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
7. Patient-centric Comparability Assessment of Biopharmaceuticals.
Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
[TBL] [Abstract][Full Text] [Related]
8. An industry perspective approach and control strategy for implementation of ready-to-use cells in bioassays: survey outcome and recommendations.
White JR; Ahmed S; Amstrup J; Bennington P; Cheng ZJ; Day P; Haenssen KK; Kozminsky-Atias A; Martinez E; Ong EH; Qahwash I; Stokes ES; Wang J
Biotechniques; 2024 Apr; 76(4):135-144. PubMed ID: 38334496
[TBL] [Abstract][Full Text] [Related]
9. Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
Kretsinger J; Frantz N; Hart SA; Kelley WP; Kitchen B; Novick S; Rellahan B; Stranges D; Stroop CJM; Yin P; Gastens MH
J Pharm Sci; 2019 Apr; 108(4):1442-1452. PubMed ID: 30528942
[TBL] [Abstract][Full Text] [Related]
10. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
Gikanga B; Chen Y; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
[TBL] [Abstract][Full Text] [Related]
11. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical Stability of Monoclonal Antibodies: A Review.
Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V
J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737
[TBL] [Abstract][Full Text] [Related]
14. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
Zhuang Y; Chen D; Sharma A; Xu Z
AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
[TBL] [Abstract][Full Text] [Related]
15. A Streamlined Bioanalytical Approach to Select a Compatible Primary Container System Early in Drug Development: A Toolbox for the Biopharmaceutical Industry.
Singh R; Waxman L
J Pharm Sci; 2020 Jan; 109(1):206-210. PubMed ID: 31545968
[TBL] [Abstract][Full Text] [Related]
16. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
[TBL] [Abstract][Full Text] [Related]
17. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
Mantle JL; Lee KH
PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
[TBL] [Abstract][Full Text] [Related]
18. Next Generation Biopharmaceuticals: Product Development.
Mathaes R; Mahler HC
Adv Biochem Eng Biotechnol; 2018; 165():253-276. PubMed ID: 29637223
[TBL] [Abstract][Full Text] [Related]
19. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
[TBL] [Abstract][Full Text] [Related]
20. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
